Document:

EX-10.33

 Exhibit 10.33 

 

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

AMENDMENT NO. 1 TO THE 
 LICENSE AGREEMENT EFFECTIVE FEBRUARY 1, 2006 
 BETWEEN STANFORD UNIVERSITY

 AND 
 FIVE PRIME THERAPEUTICS INC. 
 Effective as of January 22, 2010 (“Amendment
Effective Date”), The Board Of Trustees of the Leland Stanford Junior University (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Five Prime Therapeutics, Inc.
(“Five Prime”), a company having a primary place of business at 1650 Owens Street, Suite 200, San Francisco, CA 94158, agree to enter into this Amendment No. 1 (“Amendment”) as follows: 

 

	 	1.	BACKGROUND 

 Stanford has
an assignment of an invention to produce *** that can be used to express proteins in vivo and serve as ***. It is described in Stanford Docket *** entitled “***” and Stanford Docket *** entitled “***,”
and was invented in the laboratory of Dr. ***. 
 Stanford and Five Prime are parties to a License Agreement effective as of
February 1, 2006 (“Original Agreement”) that covers the invention disclosed in Stanford Docket ***. 
 Five Prime
and Stanford entered into a Letter Agreement on October 14, 2009 by which Stanford made biological materials under Stanford Docket *** available to Five Prime for *** months for evaluation purposes. As a result of its evaluation, Five Prime
wishes to obtain certain rights from Stanford and Stanford wishes to grant Five Prime such rights. 
 Stanford and Five Prime
hereby agree to amend the Original Agreement to include rights to the patent rights and biological materials under the Stanford Docket ***, under the terms and conditions set forth below. 

 

	 	2.	AMENDMENT 

  

	 	A.	The following paragraph is added to the end of Section 1: Background of the Original Agreement: 

“In addition, the Invention includes Stanford Docket *** entitled “***,” which was also invented in the
laboratory of Dr. ***. The Parties executed a Letter Agreement on October 14, 2009 by which Stanford made biological materials covered under Stanford Docket *** available to Five Prime for *** months for evaluation
purposes (“Second MTA”). The terms and conditions of this Agreement are intended to supersede the terms and conditions of the Second MTA.” 
  

	 	B.	Section 2.1: “Biological Materials” of the Original Agreement is deleted in its entirety and replaced by the following: 

“2.1 “Biological Materials” means the *** or *** plasmids; the ***; the ***; and the ***
plasmid.” 

	 	C.	Section 2.3: “Licensed Patent” of the Original Agreement is deleted in its entirety and replaced by the following: 

“ “Licensed Patent” means: 
 (A) Stanford’s U.S. Patent Application Serial Number ***, filed ***; Stanford’s U.S. Patent Application Serial ***, filed ***; Stanford’s U.S. Patent Application
Serial Number ***, filed ***; Stanford’s U.S. Patent Application Serial Number ***, filed ***; and any foreign or international patent application corresponding thereto, and any priority, divisional, continuation, or
reexamination application, and each patent that issues or reissues from any of these patent applications or their parents (collectively, the “*** Patent”); 
 (B) claims *** of Stanford’s U.S. Patent No. *** and any reexamined or reissued claims corresponding thereto (the “*** Patent”). 

Any claim of an unexpired Licensed Patent is presumed to be valid unless it has been held to be invalid or unpatentable by the U.S.
Patent and Trademark Office (“USPTO”), a final judgment of the Board of Appeals of a Patent Office or a court of competent jurisdiction from which no appeal can be or is taken. “Licensed Patent” excludes any continuation-in-part
(CIP) patent application or patent maturing therefrom to the extent that the issued claims in such cannot be supported by its parent application in the absence of the additional material in the CIP application.” 

 

	 	D.	Section 3.2 of the Original Agreement is deleted in its entirety and replaced by the following: 

“Non-exclusivity and Term. The license granted herein is non-exclusive in the Licensed Field of Use for a term beginning on
February 1, 2006 and ending when the last Valid Claim of the *** Patent expires or when all claims of the *** Patent are abandoned or no U.S. patent issues from the *** Patent within ten (10) years after the Effective
Date (“Term”). If FivePrime wants a license to the Biological Materials upon expiration of this Agreement, Stanford and FivePrime agree to negotiate a license to the Biological Materials in good faith and on commercially reasonable terms.

  

	 	E.	Section 6.2 of Original Agreement is deleted in its entirety and replaced by the following: 

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 2

 “License Maintenance Fee. FivePrime shall pay Stanford a yearly license
maintenance fee, during the Term of this Agreement, as follows: 
 6.2.1*** Dollars ($***) on each of
February 1, 2007, February 1, 2008, and February 1, 2009; and 
 6.2.2*** ($***) on
February 1, 2010 and on each February 1 thereafter.” 
  

	 	F.	Section 6.3 of the Original Agreement is deleted in its entirety. 

  

	 	3.	OTHER TERMS 

  

	 	3.1	All other terms of the Original Agreement not otherwise amended herein remain in full force and effect. 

THIS SPACE IS INTENTIONALLY LEFT BLANK 

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 3

	 	3.2	The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original
signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 1 in duplicate originals by their duly authorized officers or
representatives. 
  

			
	THE BOARD OF THE TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
		
	Signature	 	  /s/ Katharine Ku

	Name	 	KATHARINE KU
	Title	 	DIRECTOR TECHNOLOGY LICENSING
	Date	 	 February 10, 2010

	
	FIVE PRIME THERAPEUTICS INC.
		
	Signature	 	  /s/ Julia P. Gregory

	Name	 	Julia P. Gregory
	Title	 	President & CEO
	Date	 	2. 16. 10

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 4EX-10.34

 Exhibit 10.34 

 

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 Date:
October 16, 2003 
 TECHNOLOGY LICENCE AGREEMENT 

 

			
	 BETWEEN:
 whose head office address is:
	  	 NATIONAL RESEARCH COUNCIL OF CANADA
 1200 Montreal Road
 Ottawa, Ontario K1A 0R6
 Canada                                 
       (called “NRC”)

		
	(through its Institute, whose name and address are:	  	 BIOTECHNOLOGY RESEARCH INSTITUTE (BR1)
 6100 Royalmount Avenue
 Montreal, Quebec H4P 2R2

Canada                        
                (called the “Institute”)

		
	 AND:
 whose address
is:
	  	 FIVE PRIME THERAPEUTICS INC.
 a corporation under the laws of Delaware
 951 Gateway Blvd

South San Francisco
 CA 94080
U.S.A.                        (called the “Licensee”)

 WHEREAS 
  

	(a)	NRC owns or controls certain technology, which is subject to intellectual property rights, including without limitation inventions (which may be protected by patents),
copyright, trade secrets, know-how, and information that is confidential. 

  

	(b)	NRC and the Licensee desire to enter into a licence agreement that will permit the technology to be used for commercial purposes. 

IN CONSIDERATION of the following terms, conditions, promises, and payments, the parties agree as follows: 

 

	1.	DEFINITIONS IN THIS AGREEMENT 

 For all purposes of this Agreement the following terms, in singular or plural form as appropriate to the context, are defined as follows: 

 

	 	1.1	“NRC Technology” means the inventions (not necessarily patentable), trade secrets, know-how, samples, biological materials, and technical
information (confidential or not) relating to *** Vectors (defined in ANNEX 1 attached). 

  

	 	1.2	 “Patents” means the following patents and patent applications, plus any divisions, continuations, continuations-in-part, re-issues,
and extensions of these patents and patent applications plus any other patents and patent 

  
 Page 1

	 	
applications in countries within the Territory, covering essentially the same inventions or claiming priority of patenting rights from any other patent application within the Patents: ***.

  

	 	1.3	“NRC Intellectual Property Rights” means Patents and other exclusionary rights in respect of the NRC Technology, and rights in respect of Confidential
information included in the NRC Technology. 

  

	 	1.4	“NRC’s Internal Purposes” means research and development within NRC’s laboratories and the provision of services to NRC’s customers,
conducted in such a way as to avoid the transfer or disclosure of either confidential information of the Licensee or confidential information of NRC which is deliverable under this Agreement and whose disclosure would deprive the Licensee of some
significant advantage intended by this Agreement. 

  

	 	1.5	“Product” means any thing (including equipment, system, device, component, chemical, molecule, database, or software) that incorporates or embodies or
is derived from any part of the NRC Technology (including all modifications made by the Licensee or NRC), or that results from practicing or using the NRC Technology, and also any document that relates to the NRC Technology.

  

	 	1.6	“Service” means any service to third parties, not provided free, that is provided by using any part of the NRC Technology (including all modifications
made by the Licensee or NRC), or by using a Product, or that relates to a Product, including (without limiting the generality of the foregoing) customization, maintenance, installation, training, consulting, testing, operating, dissemination of
advertising or publicity, production, packaging and distribution. 

  

	 	1.7	“Affiliate” is a corporation of which more than 20% of the voting shares are owned by the Licensee, or which owns more than 20% of the voting
shares of the Licensee, or of which more than 50% of the voting shares are owned by another Affiliate or if it owns more than 50% of another Affiliate. 

  

	 	1.8	“Arm’s length” has the meaning as used for purposes of the Income Tax Act of Canada, and is not limited to the same meaning as being an
Affiliate. 

  

	 	1.9	“Territory” means worldwide. 

  

	2.	GRANT OF LICENCE 

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 Page 2

	2.1	Selling Grant: NRC grants to the Licensee a licence of NRC’s Intellectual Property Rights effective throughout the Territory: 

 

	 	(a)	to reproduce, make, use, import and Sell any Product and export any Product to any place within the Territory; 

 

	 	(b)	to engage contractors to reproduce or make any Product to be used or sold by the Licensee; 

 

	 	(c)	to Sell any Service. 

  

	2.2	Field of Use: The Licensee shall not deal in any manner with Products, Services or NRC Technology except as authorized under this Agreement for
applications within the Territory and within the authorized field of use, which is: Internal use, including bona fide research collaborations with third parties for Expression of recombinant proteins by Transient Transfection, provided that such
collaborations are not solely based on recombinant protein expression technology incorporating NRC Technology. 

  

	2.3	Exclusivity: The rights granted to the Licensee by way of licence under this Agreement are non-exclusive. 

 

	2.4	Sub-licensing: The Licensee may sub-license the rights granted by this Agreement to purchasers of a Product, as needed to permit normal use of a Product by an
end-user and such sub-licences survive termination of this Agreement. 

  

	2.5	Canadian Content: The Licensee shall make diligent efforts to produce Products in Canada or to maximize the use of Canadian-made materials in Products to the
extent that they are reasonably available. Canadian-based sub-licensees shall be subject to the same requirement. Foreign-based sub-licensees are not so restricted. 

 

	2.6	Delivery: NRC shall give the Licensee a copy of all of NRC’s relevant: 

 

	 	(a)	Patents, including the latest draft of any applications that have not matured into patents; 

 

	 	(b)	documentation that is reasonably necessary for an understanding of the NRC Technology and for implementation thereof, to the extent that it exists, including standard
implementation protocols; 

  

	 	(c)	samples, in reasonable quantities, of materials illustrating the NRC Technology. 

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 Page 3

 The Licensee shall be conclusively deemed to have received all necessary delivery under this
paragraph if the Licensee has not notified NRC, within *** days after the effective date of this Agreement, that delivery is lacking. 
  

	3.	FEES AND ROYALTIES 

  

	 	3.1	Licence Fee: As consideration for the grant of a fully paid-up, worldwide, royalty-free licence, immediately upon receiving a fully signed original of this
Agreement the Licensee shall pay NRC the sum of USD $ *** plus applicable taxes. 

  

	 	3.2	Tax: The Goods and Services Tax, or Harmonized Sales Tax, or Quebec Sales Tax, is applicable to payments required by this Agreement, depending on the residence
of the Licensee or sub-licensee, while none of those taxes normally applies to foreign-based payers. It is the responsibility of the payer, whether Licensee or sub-licensee, to determine tax status and to pay the applicable tax. NRC’s GST and
HST registration number is ***. NRC’s QST registration number is ***. 

  

	 	3.3	Interest: In lieu of the regulation that requires NRC to charge interest on overdue amounts at a rate based on *** must be paid on overdue amounts from
the date when payment is due until the date it is received by NRC. ***. An administrative charge of $25 will be invoiced for any cheque, which is refused payment by the financial institution on which it is drawn. 

 

	 	3.4	Delinquent Accounts: NRC may use a collection agency to collect any debt arising under this Agreement, and NRC may obtain a set-off of the debt against any other
money payable by the Government of Canada to the Licensee. The costs and fees of collection agencies shall be added to the debt payable to NRC. 

  

	4.	INTELLECTUAL PROPERTY 

  

	 	4.1	 Patenting Responsibility: NRC shalt bear the responsibility and pay the cost to obtain and maintain Patents in the countries that NRC chooses to
file an application directly or through the national phase of a PCT application. NRC shall use reasonable efforts to obtain those Patents and shall not allow those Patents to lapse for failure to comply with maintenance obligations. If applications
(including the national phase of a PCT application) could be filed in countries which NRC has not chosen, they may be requested by the Licensee and shall be filed by NRC if the Licensee bears all expenses

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 Page 4

	 	
including without limitation the reasonable cost of maintaining those Patents provided that Licensee is granted a non-exclusive license to the NRC Technology in such countries.

  

	 	4.2	Patent Marking: If the Licensee markets Products in the U.S. and a U.S. Patent applies, the Licensee shall, and shall require sub-licensees to, mark all Products
with the Patent numbers so as to obtain the full benefit of U.S. law. 

  

	5.	TECHNICAL ASSISTANCE 

  

	 	5.1	No Assistance: NRC is not obliged to provide the Licensee with technical assistance relating to the NRC Technology or the Product. NRC may, at its sole
discretion, supply technical assistance under separate contracts, in accordance with NRC’s customary terms and standard rates. 

  

	 	5.2	Licensee’s Improvements or Additions: In the event that the Licensee produces additions or changes to the NRC Technology, which by their nature could not be
made or used without some use of the NRC Technology (hereafter, “Licensee Technology”), the Licensee shall provide NRC, within *** (***) days from the time the additions or changes have been made, with all available technical
information concerning them, including source code if software is involved, and shall be deemed to license NRC to use them for NRC’s Internal Research Purposes at no cost to NRC. 

 

	 	5.3	Grant Back: Upon Termination of this Agreement, the Licensee shall be deemed to have granted to NRC, and shall execute any documents reasonably required by NRC
as additional evidence of this, a non-exclusive, perpetual royalty-free licence to Licensee Technology unless this Agreement is terminated for breach thereof, with no right to sublicense, to make or use articles incorporating any additions and
changes made by the Licensee for NRC’s Internal Research Purposes, which were required by the preceding paragraph to be reported to NRC, whether patentable or unpatentable, without any obligation to account to the Licensee.

  

	6.	CONFIDENTIALITY 

  

	 	6.1	 What is Confidential: The NRC Technology is confidential to NRC except for published elements and elements, which NRC states in writing to be
not confidential. Software source code is confidential to NRC. The Licensee’s derivative software is confidential to the Licensee, unless the Licensee states otherwise in writing. Any documents of either party, marked

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 Page 5

	 	
“Confidential”, “Protected”, “Proprietary”, or similar words, are confidential to that party. Licensee Technology, if any, is confidential to Licensee.

  

	 	6.2	Obligations of Confidentiality: Except to the extent particularly expressly authorized in this Agreement, each party shall, until *** years after the
expiration date defined in paragraph 11.1, protect the other party’s confidential information with some degree of care as it uses to protect its own confidential information, but not less than a reasonable degree of care, and shall not use such
information for purposes other than those contemplated by this Agreement. Disclosure of information by a receiving party is permitted to the extent that it can be proved to be: 

 

	 	(a)	independently developed by the receiving party without reference to or use of the confidential information of the other party; 

 

	 	(b)	received from the third party without breach of any obligation of confidentiality; 

 

	 	(c)	in the public domain at the time of its disclosure or that later becomes publicly available without breach of this Agreement; or 

 

	 	(d)	required to be disclosed by law, including in the case of NRC, the Access to Information Act, provided that the receiving party first provides the disclosing party with
notice of such requirements and of its intent to disclose the information and provides the disclosing party a reasonable opportunity to minimize the disclosure or minimize the effect of such disclosure. 

 

	 	6.3	If Confidentiality Lost: This Agreement remains in effect regardless of any loss of confidentiality of the NRC Technology or Licensee Technology at any time for
any reason, although each party retains the right to terminate this Agreement for a breach by the other party. 

  

	7.	USE OF NRC’S NAME 

  

	 	7.1	Control of Use: NRC reserves the right, in its sole discretion, to control any unauthorized use of its name and may notify the Licensee that it must immediately
cease using the name, including any abbreviations, words, or images that imply an association with NRC. Upon receipt of such notification, the Licensee must use its best efforts to withdraw from circulation any written material that represents an
unauthorized use. 

  

	 	7.2	 Authorized Use: Notwithstanding any other provision of this Agreement, NRC hereby authorizes the Licensee, and the Licensee

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 Page 6

	 	
agrees to take all reasonable opportunities, such as in sales literature or press releases, to acknowledge NRC as the source of the NRC Technology, but not so as to imply, in any such
acknowledgment, that NRC endorses or approves any Product or Service offered for Sale by the Licensee. 

  

	8.	WARRANTIES, DISCLAIMERS AND INDEMNITIES 

  

	 	8.1	Warranty of Licensing Rights: NRC warrants that it has not previously granted any rights that would conflict with the rights granted by this Agreement. NRC
warrants that it is either the owner or the licensee (with power to sub-license) of all copyrights and Patents licensed by this Agreement. 

 ***. 
  

	 	8.2	No Implied Warranties: Except for representations, warranties or conditions expressly made in this Agreement, the NRC Technology or Licensee Technology, if any,
is supplied and licensed on an “as is” basis, and there are no representations, warranties or conditions, express or implied by statute, including without limitation any with respect to: 

 

	 	(a)	market readiness, merchantability, or fitness for any use or purpose; 

  

	 	(b)	operational state, character, quality, or freedom from defects; 

  

	 	(c)	non-infringement of rights of third parties under present or future patents. 

 

	 	8.3	No Contestation of Validity: The Parties acknowledge the validity of the Patents and copyright licensed hereunder and agrees not to contest such validity during
the life of this Agreement, either directly or indirectly by assisting other parties. This clause is not operational under U.S. law. 

  

	 	8.4	Limited Damages: NRC shall not be liable, in any event, for consequential or incidental damages, or loss of income, arising from the possession or use of the NRC
Technology licensed or conveyed pursuant to this Agreement. 

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 Page 7

	 	8.5	Indemnity: NRC rejects all liability and responsibility relating to the consequences of using the Products or providing Services. The Licensee shall indemnify
and save harmless NRC, its employees and agents from and against, and be responsible for the following to the extent that they arise from Licensee’s actions and they are not caused by negligence or intentional misconduct of NRC:

  

	 	(a)	all claims, demands, losses, damages, costs including solicitor and client costs, actions, suits or proceedings brought by any third party, that are in any manner based
upon, arising out of, related to, occasioned by, or attributable to: 

  

	 	(i)	the manufacturing, distribution, shipment, offering for Sale, Sale, or use of Products, Services or the NRC Technology by Licensee; and 

 

	 	(ii)	product liability and infringement of intellectual property rights other than copyright by Licensee; 

 

	 	(b)	other reasonable costs, including extra-judicial costs, of NRC defending any such action or proceeding, which NRC shall have the right to defend with counsel of its
choice. 

  

	 	This	clause shall survive expiration or termination of this Agreement. 

  

	9.	INFRINGEMENT LITIGATION 

  

	 	9.1	Initial Consultation: If the Licensee receives or become aware of any claim or assertion by a third party that any activities by the Licensee under this
Agreement constitute an infringement or other violation of a third party’s patents or other intellectual property, the Licensee shall notify NRC and shall provide NRC with all details relating to the allegation. The parties shall promptly enter
into discussions with the third party to determine the extent and validity of the infringement claim and the parties’ mutually agreed course of action. Notwithstanding other provisions herein. Each party will absorb its own costs of the
discussions. 

  

	 	9.2	Negotiation: The parties may negotiate with a third party, to obtain any additional rights required, such as may arise if a third party’s patent emerges.
Each party will absorb its own costs of negotiation. If those additional rights require payment, the parties will negotiate for a reduction in royalties payable to NRC, and failing agreement within *** (***) days, either party may
invoke the arbitration procedure in this Agreement to settle the amount of the reduction of the royalty. 

  

	 	9.3	 Legal Action: The parties may agree to jointly defend or pursue litigation, but neither party shall bind or commit the other party to any course
of action, which involves liability for legal costs, expenses, or damages. If the parties 

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 Page 8

	 	
fail to agree, within a reasonable time having regard to the normal progress of litigation, as to any course of action which might be jointly taken, either party may take or defend proceedings
alone, if legally entitled to act alone, and shall be entitled to retain any amount awarded to it by a court, or paid to it as a settlement by the third party, and the excess of that amount over costs reasonably incurred by both parties for the
settlement or litigation, shall be regarded as Sales Revenue of a sub-licensee for the purpose of calculating royalties. If one party wishes to act alone but formalities require participation of the other party, the other party shall join in the
proceeding to the extent necessary for formalities. Each party will cooperate with the other in making available all necessary documents and witnesses for any legal proceeding, without fees. A party proceeding alone (or with one party as a
formality) shall indemnify the other party for reasonable legal costs for representation that is reasonably necessary, and for any court-ordered payments. 

  

	 	9.4	Damages for Infringement: If the parties (and not with one party participating only as a formality) have jointly pursued an infringer by litigation and the
Licensee obtains money from the infringer as a settlement or by court order, the excess of that money above the Licensee’s costs that were reasonably incurred for the settlement or litigation, shall be regarded as Other Revenue in relation to a
sub-licence. 

  

	10.	DURATION AND TERMINATION  

  

	 	10.1	 Expiration: This Agreement shall become effective when it has been signed by both parties. Unless terminated earlier, this Agreement shall
terminate on December 31st, 2008. 

  

	 	10.2	Termination by Either Party for Default or Breach: In the event that one party defaults or breaches any of the provisions of this agreement, the other party
shall have the right to terminate this Agreement by giving written notice to the defaulting party, but this act shall not prejudice the right of NRC to recover any fee due at the time of such termination and shall not prejudice any cause of action
or claim of NRC accrued or to accrue on account of any breach or default by the Licensee. However, if the defaulting party cures the breach within *** (***) days after the notice is given, this Agreement shall continue in full force
and effect. 

  

	 	10.3	Termination by NRC: This Agreement, at the option of NRC, may be terminated forthwith by NRC if the Licensee becomes bankrupt, or insolvent, or has a receiver
appointed to continue its operations, or passes a resolution for winding up, or takes the benefit of any statute relating to bankrupt or insolvent debtors or the orderly payment of debts. 

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 Page 9

	 	10.4	Procedure on Termination: Upon termination the Licensee shall: 

  

	 	(a)	deliver a detailed statement to NRC of the inventory of all commercial Products then existing and not Sold by the Licensee as at that date; 

 

	 	(b)	retain the right to Sell Products then existing for a period of *** provided that any remaining inventory of Products shall be destroyed by the License at the
end of that ***; 

  

	 	(c)	retain the right to deliver Services for which a contractual commitment has been made before the Termination, for a period of ***; and 

 

	 	(d)	cease any other use of the NRC Technology unless the NRC Technology, in total, has then become part of the public domain other than through any act or omission of the
Licensee. 

  

	 	10.5	Accrued Obligations: Termination does not release a party from any obligations, which accrued while this Agreement was in force or upon its termination.

  

	11.	LAW AND DISPUTES 

  

	 	11.1	Choice of Law: This Agreement shall be interpreted according to the laws of the Province of Quebec and the laws of Canada in force there.

  

	 	11.2	Courts: Any litigation concerning this Agreement, including litigation arising from arbitration, shall be brought only in a court, which has ordinary
jurisdiction over the defendant on the basis of residence, and the residence of NRC for this purpose shall be regarded as the location of the Institute. 

  

	 	11.3	 Dispute Resolution: Both parties will use reasonable efforts to reach an amicable negotiated settlement of any dispute concerning the
interpretation or operation of this Agreement. Disputes concerning this Agreement shall not be litigated. If negotiation fails to resolve a dispute within *** (***) days, either party can require non-binding mediation, whereupon the
parties shall jointly appoint one impartial expert mediator to mediate according to mutually agreed procedures. If a party refuses to effectively participate in mediation, or if mediation continues for more than *** (***) days, either
party can require binding arbitration under the Commercial Arbitration Act of Canada, whereupon the parties shall attempt to jointly appoint one impartial expert arbitrator. If the parties cannot agree within *** (***) days on the

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 Page 10

	 	
choice of an arbitrator, each party shall appoint its own arbitrator and those arbitrators shall jointly appoint a chairperson of an arbitral tribunal. An arbitral award shall not include
punitive damages, or interim measures. Each party shall pay its own costs and an equal share of all other costs of mediation and arbitration, except for the exceptional circumstance in which an arbitral award may require the payment of all costs by
a party who has brought a plainly frivolous dispute. Unless otherwise agreed by the parties when the occasion arises, mediation and arbitration shall be held in the city where the *** is located. This provision survives the Termination of
this Agreement. 

  

	12.	GENERAL TERMS AND CONDITIONS 

  

	 	12.1	Entire Agreement: This Agreement represents the entire understanding between the parties as of the effective date hereof, and supersedes all prior
communications, negotiations and agreements, written or oral, concerning the NRC Technology. 

  

	 	12.2	Limits of Agreement: For greater certainty, the parties agree that this is not an assignment of ownership of copyright or of patent rights, but merely a
licence. This Agreement shall not be construed as creating the relationship of principal and agent, employer and employee, partnership, or joint venture. 

  

	 	12.3	Amendments: This Agreement may only be amended by an agreement in writing, signed by the parties, expressly referring to this Agreement.

  

	 	12.4	Severance: If any provision in this Agreement is found, by a court or arbitration, to be wholly or partly invalid, illegal or unenforceable in any respect, the
remainder of this Agreement shall remain enforceable and this Agreement shall be construed as if that provision had never existed. The request to initial each page is not a condition of this Agreement. 

 

	 	12.5	Waiver: Failure by either party to assert rights arising from any breach or default of this Agreement, or acceptance of payments, shall not be regarded as a
waiver of rights. No failure to assert rights, no waiver, and no toleration implies any continuing or future waiver of rights. 

  

	 	12.6	 Assignment: This Agreement is personal to the parties, so that neither its assignment, nor its assumption by a corporation formed by
amalgamation with a party is valid without the other party’s written consent, which consent shall not be unreasonably withheld; provided, however, that either Party may assign this Agreement and its rights and obligations hereunder without the

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 Page 11

	 	
other party’s consent in connection with the transfer or sale of all or substantially all of the business of such party to which this Agreement relates to a third party, whether by merger,
sale of stock, sale of assets or otherwise. 

  

	 	12.7	Force Majeure: Neither party shall be responsible or liable to the other for failure or delay in the performance of this Agreement due to war,
fire, accident or other casualty, labour disturbance, act of the public enemy, act of God, or any other contingency beyond that party’s reasonable control. In the event of applicability of this paragraph, the party affected by such force
majeure shall use its best efforts to eliminate, cure and overcome any such causes and resume performance of its obligations as soon as possible. 

  

	 	12.8	Notices: Any notice contemplated by this Agreement, unless a different address is subsequently notified by one Party to the other in writing, must be sent to the
address stated at the beginning of this Agreement where the Parties are identified, by: 

  

	 	(a)	registered mail, and then it is deemed to be an effective notice *** (***) days after it is sent, 

 

	 	(b)	courier, and then it is an effective notice only when acknowledged by an official receipt, or 

 

	 	(c)	by personal delivery to the office of the chief executive officer of the Party, and then it is an effective notice only when acknowledged by a signature of either that
person or a person with apparent authority to receive messages. 

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 Page 12

 ANNEX 1. – LIST OF *** VECTORS 

*** 

  

	***	INDICATES ONE PAGE OF MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 Page 13 

 SIGNED by the Licensee in duplicate at 951 Gateway Blvd, South San Francisco, CA 94080, U.S.A.

  

							
		 		 	FIVE PRIME THERAPEUTICS INC
				
	Date: Oct. 21, 2003	 		 	Per:	 	  /s/ Gail Maderis

		 		 		 	Gail Maderis, President and CEO

 SIGNED by NRC in duplicate at Montreal, Quebec, Canada. 

 

							
		 		 	NATIONAL RESEARCH COUNCIL OF CANADA
				
	Date: Oct. 23, 2003	 		 	Per:	 	  /s/ Michel J. Desrochers

		 		 		 	Michel J. Desrochers, Director General — BRI

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 Page 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]